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SUPPRESSION OF 12-O-TETRADECANOYLPHORBOL-13-ACETATE INDUCED 
ORNITHINE DECARBOXYLASE ACTIVITY BY RESVERATROL DERIVATIVES
Suaib Luqman1,2, Tamara P. Kondratyuk1, Juma Hoshino3, Mark Cushman3, John M. Pezzuto1*
Compounds Inhibition (%) Survival (%)
JH 2-18 94.27 0.55 68.2 14.3
JH 2-23 90.55 4.49 71.9 17.2 
JH 2-44 98.15 0.08 99.5 4.1
JH 2-61 97.85 0.66 56.6 16.7
JH 3-3 96.17 1.3 60.5 19.1
JH-3-37 95.07 0.97 67.0 18.6
JH-3-39 90.8 2.15 66.4 22.9
JH-3-46 96.2 0.44 78.1 11.4
JH-4-15 95.12 0.41 74.4 8.7
JH-4-58 93.52 0.14 73.8 3.1
JH-4-56 97.27 0.03 84.4 17.5
JH-4-59 91.07 2.7 89.6 7.1
SB-I-29 90.34 6.5 48.1 12.0
SB-I-35 95.42 0.23 58.0 2.6
SB-I-36 95.35 1.15 64.1 8.0
SB-I-37 95.80 0.58 79.8 5.2
SB-I-42 94.87 2.39 52.9 9.2
SB-I-43 92.26 0.34 58.7 25.0
SB-I-45 93.49 3.92 77.7 6.3
SB-I-49 97.86 0.45 94.9 30.2
SB-I-54 47.62 7.2 53.4 10.5
SB-I-56 97.78 0.24 62.6 14.9
Resveratrol 96.09 1.82 99.1 11.7
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mRNA Expression Analysis
 JH 2-23 showed highest inhibition (99.0 ± 5.0 %) and Resveratrol lowest (58.0 ± 2.6
%).
 The order of inhibition for other samples was as follows:
JH 2-44= JH 3-39= JH 4-15> JH 4-58> JH 4-56> JH 3-3> SB I-56> JH 2-61> JH 4-59>
JH 3-46> JH 3-37> SB I-54> JH 2-18> SB I-37> SB I-49> SB I-36> SB I-35> SB I-45> SB
I-42.
Inhibition of PKC activity
 JH 2-23 showed maximum inhibition of PKC activity
 The inhibition of PKC activity: SB I-36> JH 2-44>SB I-56= SB I-54=SB I-43>
SB I-45> JH 3-39= JH 3-37= JH 4-58> JH 3-3 = SB I-37 > JH 4-59=SB I-42=
SB I-49=JH 2-61=SB I-29> SB I-35=JH 3-46.
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Inhibition of TPA induced Ornithine decarboxylase activity
 JH 4-15 showed maximum inhibition of  ODC activity at IC50  1.21µM
 The IC50 values for the resveratrol derivatives were found to be in the 
following order: JH 2-23>JH 3-46> SB I 49>SB I 43>SB I 37> SB I 56> 
SB I 36>JH 3-39>JH 2-44> SB I 42>SB I 45> SB I 54> JH 3-37>JH 2-
18>JH 2-61>JH 3-3>SB I 29>SB I 35>JH 4-58>JH 4-56> JH 4-59>JH 4-
15. 
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Resveratrol
 Resveratrol (3,4,5-trihydroxy-trans-stilbene), a phytoalexin found in grape skins, peanuts, and red wine, have a potent chemopreventive effect in multiple carcinogenesis models
both in vivo and in vitro.
 Resveratrol and its analogues are known to interfere with signal transduction pathways, where they inhibit activities of various protein kinases which in turn declines the
expression of nuclear proto-oncogenes and the activity of ornithine decarboxylase (ODC) is reduced.
 ODC activity and expression have been among the first biomarkers of neoplastic proliferation and catlyzes the rate- limiting step in polyamine biosynthesis.
 ODC activity is essential for cell proliferation and is required for progression into the S phase of the cell cycle.
 TPA induction of ODC mRNA expression and ODC activity may be PKC activation dependent or independent.
RESULTS
Possible mode of action of Resveratrol and effect of putrescine on signal 
transduction pathways of cell proliferation
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PKC activation Accumulation of 
epidermal 
prostaglandins
Increase in the 
lipoxygenase
products
Microtubule 
containing Systemin
Regulation
Free radical 
generation
ODC mRNA expression
Molecular Mechanisms For ODC induction by TPA
 Our studies depicts potential metabolites having greater activity [tetrabutylammonium (E)-4-(3,5-dihydroxystyryl)phenyl sulfate (IC50 1.2 µM), resveratrol
tripotassium 3,5,4'-trisulfate (IC50 1.8 µM), resveratrol tripotassium 3,4'-disulfate (IC50 1.8 µM), and resveratrol tripotassium 3,5-disulfate (IC50 2.3 µM)], than the
resveratrol on human bladder epithelial carcinoma HTB-24 cells in culture
 TPA-increased amount of ODC mRNA may be the result of enhanced ODC gene transcription and/or decreased degradation of ODC mRNA.
 During ODC induction by TPA, the increase in its mRNA is usually much less than the observed activity, suggesting that some regulation of ODC activity occurs
posttranscriptionally.
 Some of the resveratrol derivatives, doesnot show any significant inhibition of PKC activity although inhibiting the ODC activity at very low concentration of
1.2µM, suggesting their mode of action which is PKC independent.
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